Evidence map›Paper›PMID 41089484›Full record

ArticleACS medicinal chemistry letters2025

Design and Synthesis of Pyrazoline Inhibitors of SARS-CoV‑2 NSP14.

Elliott B Smyth, João P Pisco, Kristian Birchall, Nicole S Upfold, Arvind H Patel, Richard Foster, Jonathan M Large

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. ACS medicinal chemistry letters · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elliott B SmythLifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, U.K.ORCID https://orcid.org/0009-0006-3717-2684
João P PiscoLifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, U.K.ORCID https://orcid.org/0000-0001-6763-7354
Kristian BirchallLifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, U.K.
Nicole S UpfoldMRC-University of Glasgow Centre for Virus Research, Sir Michael Stoker Building, Garscube Campus, 464 Bearsden Road, Glasgow G61 1QH, U.K.
Arvind H PatelMRC-University of Glasgow Centre for Virus Research, Sir Michael Stoker Building, Garscube Campus, 464 Bearsden Road, Glasgow G61 1QH, U.K.ORCID https://orcid.org/0000-0003-4600-2047
Richard FosterSchool of Chemistry, University of Leeds, Leeds LS2 9JT, U.K.ORCID https://orcid.org/0000-0002-2361-3884
Jonathan M LargeLifeArc, Accelerator Building, Open Innovation Campus, Stevenage SG1 2FX, U.K.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-structural protein 14 (NSP14) is a key two-domain protein responsible for maintaining coronavirus replication fidelity, and in its absence reproduction is severely impacted. With the goal of identifying new inhibitors of SARS-CoV-2 NSP14, we selected a previously reported scaffold as an appropriate starting point. Medicinal chemistry exploration provided a series of trisubstituted pyrazolines as inhibitors of NSP14 methyltransferase (MTase) activity, with improved synthetic tractability and in a promising molecular property space. This led to compound

Indexed as

InhibitionInhibitorsLigandsMoleculesPeptides and ProteinsSARS-CoV-2

Identifiers

PMID41089484
PMCPMC12516378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.